Back to Search Start Over

Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in Trained Men.

Authors :
Durussel, Jérôme
Daskalaki, Evangelia
Anderson, Martin
Chatterji, Tushar
Wondimu, Diresibachew H.
Padmanabhan, Neal
Patel, Rajan K.
McClure, John D.
Pitsiladis, Yannis P.
Source :
PLoS ONE; Feb2013, Vol. 8 Issue 2, p1-8, 8p
Publication Year :
2013

Abstract

Recombinant human erythropoietin (rHuEpo) increases haemoglobin mass (Hb<subscript>mass</subscript>) and maximal oxygen uptake ( O<subscript>2 max</subscript>). Purpose: This study defined the time course of changes in Hb<subscript>mass</subscript>, O<subscript>2 max</subscript> as well as running time trial performance following 4 weeks of rHuEpo administration to determine whether the laboratory observations would translate into actual improvements in running performance in the field. Methods: 19 trained men received rHuEpo injections of 50 IU•kg<superscript>−1</superscript> body mass every two days for 4 weeks. Hb<subscript>mass</subscript> was determined weekly using the optimized carbon monoxide rebreathing method until 4 weeks after administration. O<subscript>2 max</subscript> and 3,000 m time trial performance were measured pre, post administration and at the end of the study. Results: Relative to baseline, running performance significantly improved by ∼6% after administration (10∶30±1∶07 min:sec vs. 11∶08±1∶15 min:sec, p<0.001) and remained significantly enhanced by ∼3% 4 weeks after administration (10∶46±1∶13 min:sec, p<0.001), while O<subscript>2 max</subscript> was also significantly increased post administration (60.7±5.8 mL•min<superscript>−1</superscript>•kg<superscript>−1</superscript> vs. 56.0±6.2 mL•min<superscript>−1</superscript>•kg<superscript>−1</superscript>, p<0.001) and remained significantly increased 4 weeks after rHuEpo (58.0±5.6 mL•min<superscript>−1</superscript>•kg<superscript>−1</superscript>, p = 0.021). Hb<subscript>mass</subscript> was significantly increased at the end of administration compared to baseline (15.2±1.5 g•kg<superscript>−1</superscript> vs. 12.7±1.2 g•kg<superscript>−1</superscript>, p<0.001). The rate of decrease in Hb<subscript>mass</subscript> toward baseline values post rHuEpo was similar to that of the increase during administration (−0.53 g•kg<superscript>−1</superscript>•wk<superscript>−1</superscript>, 95% confidence interval (CI) (−0.68, −0.38) vs. 0.54 g•kg<superscript>−1•</superscript>wk<superscript>−1</superscript>, CI (0.46, 0.63)) but Hb<subscript>mass</subscript> was still significantly elevated 4 weeks after administration compared to baseline (13.7±1.1 g•kg<superscript>−1</superscript>, p<0.001). Conclusion: Running performance was improved following 4 weeks of rHuEpo and remained elevated 4 weeks after administration compared to baseline. These field performance effects coincided with rHuEpo-induced elevated O<subscript>2 max</subscript> and Hb<subscript>mass</subscript>. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
19326203
Volume :
8
Issue :
2
Database :
Complementary Index
Journal :
PLoS ONE
Publication Type :
Academic Journal
Accession number :
87624333
Full Text :
https://doi.org/10.1371/journal.pone.0056151